Tadalafil
Product Images NDC 71610-353

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-353). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 20 mg (71610 0353 04)

Bottle Label 20 mg (71610 0353 04)
FDA Label Image

Bottle Label 5 mg (71610 0354 23)

Bottle Label 5 mg (71610 0354 23)
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Tadalafil Structural Formula (Tadalafil Tabs 090141 1)

Tadalafil Structural Formula (Tadalafil Tabs 090141 1)
FDA Label Image

Figure 1: Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After T (Tadalafil Tabs 090141 2)

Figure 1: Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After T (Tadalafil Tabs 090141 2)
FDA Label Image

Figure 2: Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Tadalafil Tabs 090141 3)

Figure 2: Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Tadalafil Tabs 090141 3)
This appears to be a chart or table displaying blood pressure readings with the medications Tacalafi and Doxazosin being administered in different scenarios, with time post-dose being a factor. However, the chart is somewhat incomplete and without further context it is difficult to provide a more complete useful description.*
FDA Label Image

Figure 3: Doxazosin Study 2 (part C): Mean Change From Time-matched Baseline In Systolic Blood Pressure (Tadalafil Tabs 090141 4)

Figure 3: Doxazosin Study 2 (part C): Mean Change From Time-matched Baseline In Systolic Blood Pressure (Tadalafil Tabs 090141 4)
This text seems to show information related to the measurement of Systolic Blood Pressure (BP) at different times after the administration of different doses of drugs, including Tacalaf and Doxazosin. However, the text is incomplete and does not provide sufficient context to interpret the information fully. Therefore, it may not be useful for a reader without additional information.*
FDA Label Image

Figure 4: Plasma Tadalafil Concentrations (mean ± Sd) Following A Single 20 mg Tadalafil Dose And Single And Once Daily Multiple Doses Of 5 mg (Tadalafil Tabs 090141 5)

Figure 4: Plasma Tadalafil Concentrations (mean ± Sd) Following A Single 20 mg Tadalafil Dose And Single And Once Daily Multiple Doses Of 5 mg (Tadalafil Tabs 090141 5)
This is a graph showing the plasma concentration of Tadalafil at different time points (in hours) after administering different doses. The doses include a single 20 mg dose, a single 5 mg dose, and a once-daily 5 mg dose for 5 consecutive days. The concentration of Tadalafil is measured in mcg/mL, with values ranging from 0 to 400.*
FDA Label Image

Figure 5: Mean Ipss Changes In Bph Patients By Visit In Study J (Tadalafil Tabs 090141 6)

Figure 5: Mean Ipss Changes In Bph Patients By Visit In Study J (Tadalafil Tabs 090141 6)
This appears to be a table or graph showing the comparison of Tadalafil 5mg and Placebo with respect to the PSS Total Score over a period of 8 to 12 weeks of treatment. No further information can be deduced from the given text.*
FDA Label Image

Figure 6: Mean Ipss Changes In Bph Patients By Visit In Study K (Tadalafil Tabs 090141 7)

Figure 6: Mean Ipss Changes In Bph Patients By Visit In Study K (Tadalafil Tabs 090141 7)
FDA Label Image

Figure 7: Mean Total Ipss Changes By Visit In Bph Patients Taking Tadalafil For Once Daily Use Together With Finasteride (Tadalafil Tabs 090141 8)

Figure 7: Mean Total Ipss Changes By Visit In Bph Patients Taking Tadalafil For Once Daily Use Together With Finasteride (Tadalafil Tabs 090141 8)
This appears to be a graph or table showing the LS Mean Change from Baseline over 12 and 26 weeks of therapy for TadalafilFinasteride compared to Placebo/Finasteride, with a line indicating the Least-Squares Treatment Difference. Without further context or information, it is difficult to provide a more precise or useful description.*
FDA Label Image

Figure 8: Mean Ipss Changes In Ed/bph Patients By Visit In Study L (Tadalafil Tabs 090141 9)

Figure 8: Mean Ipss Changes In Ed/bph Patients By Visit In Study L (Tadalafil Tabs 090141 9)
The text describes the change in the IPSS total score for patients receiving Tadalafil 5mg compared to the placebo. The change is statistically significant (p<0.01). The duration of treatment is not provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.